Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs

Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy.

Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs.webp

Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy. Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration. Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services.

Medicilon Preclinical Ophthalmic Drug Development Platform
Help EyeCure to accelerate the development of new ophthalmic drugs

Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs-1.webp

Complementary advantages in resources and a high degree of compatibility in vision allow Medicilon and EyeCure to achieve two-way development. In this collaboration, relying on Medicilon's one-stop biopharmaceutical preclinical research and development service platform, Medicilon will provide EyeCure with services including but not limited to drug discovery, pharmaceutical research, preclinical research and comprehensive projects to assist in the development of a new class 1 ophthalmology drug.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客